New investors include Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec's Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).
The funding will support the advancement of Schrödinger's wholly-owned drug discovery pipeline and enable continued expansion of the company's collaborations with biopharma companies worldwide.
These partnerships have already led to two FDA-approved oncology drugs, several clinical-stage assets, and more than two dozen additional programmes moving through discovery and development.
The investment will also support Schrödinger's ongoing research and development efforts to extend the reach of its proprietary technology platform, which integrates novel physics-based molecular simulations and machine learning to enable exploration of vastly more chemical space than is possible through traditional drug discovery methods.
This expanded and accelerated exploration opens new frontiers for discovery of novel compounds for both therapeutic indications and materials design.
Schrödinger has a global business, licensing its computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R and D in both drug discovery and materials design.
The company has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.
Schrödinger's investment in basic research continues to drive advances in its computational platform.
Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial